Diaceutics (DXRX) Corporate presentation summary

Financial performance and growth

• Revenue grew 24% on a constant currency basis to £38.4m in FY 2025, with a 3-year CAGR of 25%.

• Adjusted EBITDA increased 80% to £7.6m, with a margin improvement from 13% to 20%.

• Annual recurring revenue (ARR) reached £20.0m, up 19% from the previous year.

• Record order book of £38.9m, with £21.1m to be recognized within 12 months.

• Returned to profitability in FY 2025, maintaining a strong balance sheet with no debt.

Operational achievements

• Number of customer therapeutic brands increased by 12% to 95.

• Secured two additional top 10 global pharma as enterprise-wide engagement customers.

• Expanded US sales team with six new hires and grew total staff to 206.

• 18 of the top 20 global pharma are now customers.

• Over 973,000 US patients identified through DXRX Signal in 2025.

Platform and technology

• AI integration automates data processing, improving speed, quality, and scalability.

• AI enhances product roadmap with smarter triggers and workflow intelligence.

• Proprietary diagnostic data and workflow integration create a defensible, differentiated platform.

• DXRX platform delivers real-time patient identification and commercial impact.